DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for postencephalitic Parkinson disease — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePostencephalitic Parkinson disease maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
approvedAmantadineApproved drugapprovedKetamineApproved drug
Structures already discussed alongside postencephalitic parkinson disease in the retrieved literature, rendered from public PubChem SMILES. Which drugs appear here reflects the evidence found, not a ranked prediction.
Molecular view
Influenza A M2 transmembrane domain — Amantadine has a real, experimentally solved structure in complex with this target (PDB 6BKK, 1.995 Å). This is the drug's own deposited structure, not a prediction, and confirms it is a structurally characterised molecule rather than an untested guess.
Loading structure…
helix sheet 308drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6BKK · 1.995 Å · ligand Amantadine (308). Experimental structure, not a prediction.
What the evidence adds up to
Levodopa is the most effective therapy for Parkinson disease, but its introduction five decades ago followed years of uncertain and equivocal clinical results. The 1974 volume *Advances in Neurology: Progress in the Treatment of Parkinsonism, vol 3* includes initial British work contrasting responses to levodopa of postencephalitic and idiopathic Parkinson disease. That volume discusses therapeutic and adverse effects of levodopa, pays attention to the "on-off" effect, and describes results of chronic treatment in a small number of patients, with the chief benefit of that essay being limited.
A 1961 paper titled "Crises in Post-Encephalitic Parkinsonism" exists, and a 1942 book *Postencephalitic Parkinsonism, Methods of Treatment* was published. No data from either of those sources on specific treatments or outcomes is available in the provided abstracts.
A 2018 program describes a plan to develop an autologous neuron replacement therapy for Parkinson disease using induced pluripotent stem cells. The authors state that the only viable treatment to reverse the progress of the disease is to replace dopamine neurons. This autologous cell therapy was entering the regulatory approval process in 2018 with the U.S. Food and Drug Administration to begin transplanting cells in the following one to two years. No results from any such transplantations are reported in the provided abstracts.
What is still missing is any controlled trial data for postencephalitic Parkinson disease specifically, any published outcomes from the stem cell approach, and any evidence that the disappointing results of early levodopa trials or the small-sample chronic treatment studies have been resolved for this patient group.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2016 · 181 citations
Levodopa therapy for Parkinson disease
AbstractAlthough levodopa is widely recognized as the most effective therapy for Parkinson disease (PD), its introduction 5 decades ago was preceded by several years of uncertainty and equivocal clinical results. The translation of basic neuroscience research by Arvid Carlsson and Oleh Hornykiewicz provided a logical pathway for treating PD with levodopa. Yet the pioneering clinicians who transformed PD therapeutics with this drug--among them Walther Birkmayer, Isamu Sano, Patrick McGeer, George Cotzias, Melvin Yahr, and others--faced many challenges in determining whether the concept and the method for replenishing deficient striatal dopamine was correct. This article reviews highlights in the early development of levodopa therapy. In addition, it provides an overview of emerging drug delivery strategies that show promise for improving levodopa's pharmacologic limitations.
AbstractJournal Article CRISES IN POST-ENCEPHALITIC PARKINSONISM Get access GILBERT ONUAGULUCHI GILBERT ONUAGULUCHI (From the Department of Materia Medica and Therapeutics, University of Glasgow, and Stobhill General Hospital) Search for other works by this author on: Oxford Academic PubMed Google Scholar Brain, Volume 84, Issue 3, September 1961, Pages 395–414, https://doi.org/10.1093/brain/84.3.395 Published: 01 September 1961
Autologous Induced Pluripotent Stem Cell-Derived Neurons to Treat Parkinson's Disease
AbstractIn 2012, we planned a program to develop a neuron replacement therapy for Parkinson's disease (PD) that would have the greatest promise to help the patients. PD is a movement disorder caused by the progressive, inevitable loss of a specific type of dopamine neuron in the brain. The only viable treatment to reverse the progress of the disease is to replace those neurons; we decided to make dopamine neurons that matched the patients, by differentiating induced pluripotent stem cells that we generated from individuals with PD. This autologous cell therapy is entering the regulatory approval process this year with the U.S. Food and Drug Administration to begin to transplant the cells in the following 1 to 2 years.
The Utility of Ketamine for the Preoperative Management of a Patient with Parkinson’s Disease
AbstractIn Brief Loss of dopaminergic neurons from the substantia nigra characterizes the classical pathology of Parkinson’s disease, but persistent activation of N-methyl-d-aspartate receptors is also a major component. During difficult airway management in a patient with advanced Parkinson’s disease, the use of low-dose (20 mg) IV ketamine resulted in complete abolition of severe tremor and dysarthria. This led to the current case report in which low-dose ketamine was used for preoperative sedation and dyskinesia attenuation. Prior research and our experience would suggest that low-dose ketamine, titrated to effect, may provide optimal patient comfort and perioperative control of Parkinsonian tremor. IMPLICATIONS: This case report describes the use of ketamine for management of a patient with advanced Parkinson’s disease resulting in complete abolition of severe dyskinesia.
Drug and Therapeutics Bulletin · 1984 · 1 citations · open access
The drug treatment of parkinson’s disease
AbstractThe symptoms of idiopathic Parkinson’s disease are due mainly to progressive degeneration of the dopaminergic nigro-striatal pathways in the brain. The drugs which can help fall into five categories: dopamine replacement, using dopa with a decarboxylase inhibitor; a dopamine agonist, bromocriptine; 1 selegiline, recently introduced, which inhibits monoamine oxidase B; anticholinergic drugs; and amantadine. 2 This article discusses recent ideas about the management of Parkinson’s disease, particularly about levodopa dosage, bromocriptine and selegiline.
American Journal of Clinical Pathology · 1942 · 0 citations
Postencephalitic Parkinsonism, Methods of Treatment
AbstractJournal Article Postencephalitic Parkinsonism, Methods of Treatment Get access Postencephalitic Parkinsonism, Methods of Treatment. van Witzleben Henry D.. Preface by Von Storch Theodore J. C., Associate Professor of Neurology, Albany Medical College. Cloth, 163 pp. Grune & Stratton, New York. American Journal of Clinical Pathology, Volume 12, Issue 10, 1 October 1942, Page 543, https://doi.org/10.1093/ajcp/12.10.543e Published: 01 October 1942
Advances in Neurology: Progress in the Treatment of Parkinsonism, vol 3
Abstract"Progress in the Treatment of Parkinsonism" is one of three volumes of the<i>Advances in Neurology</i>series, which are concerned with Parkinson disease. This third volume consists of papers presented at a symposium in January 1973 of European workers in the field. The editor comments that it was not intended as a basic text, but rather as an assessment of the state of the art. The volume admirably fulfills its purpose. It is set in delightful perspective by the preliminary remarks of Dr. J. Purdon-Martin. Therapeutic and adverse effects of levodopa are discussed in specifics. Much attention is paid to the "on-off" effect and to the initial British work contrasting responses to levodopa of postencephalitic and idiopathic Parkinson disease. Results of chronic treatment are described in a brief article by Dr. Godwin-Austen, but a small number of patients is described and the chief benefit from this essay lies in the
Supplementary Material for: Therapeutic Role of Amantadine in Prolonged Postictal Encephalopathy: A Case Report in an Elderly Patient
AbstractBackground: Prolonged postictal encephalopathy in elderly patients can be difficult to manage, especially when standard treatments fail. Amantadine, a dopaminergic agent with NMDA antagonist properties, is approved for use in Parkinson’s disease and has demonstrated efficacy in enhancing recovery in TBI. However, its role in non-traumatic etiologies such as postictal states is not well established. Case Presentation: We describe a 95-year-old man with multiple comorbidities who remained somnolent and minimally responsive for 14 days after convulsive status epilepticus, despite seizure control and metabolic correction. EEGs showed no epileptiform activity, and imaging revealed no acute pathology. A trial of amantadine 100 mg daily was initiated for suspected postictal encephalopathy. Within 48 hours, the patient showed significant improvement in alertness, orientation, and interaction, returning near baseline by day 10. Conclusion: This case suggests a potential role for amantadine in treating prolonged postictal encephalopathy in elderly patients. Further research is needed to assess its efficacy in non-traumatic disorders of consciousness.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
